東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ null ]

切換: 標籤 | MARC模式 | ISBD

Statistical Methods in Clinical Tria...

Du, Yu.

FindBook

Google Book

Amazon

博客來

Statistical Methods in Clinical Trial Design.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Statistical Methods in Clinical Trial Design./
作者:	Du, Yu.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2018,
面頁冊數:	222 p.
附註:	Source: Dissertations Abstracts International, Volume: 80-10, Section: B.
Contained By:	Dissertations Abstracts International80-10B.
標題:	Statistics. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13890134
ISBN:	9781392068441

Statistical Methods in Clinical Trial Design.
Du, Yu.

Statistical Methods in Clinical Trial Design. - Ann Arbor : ProQuest Dissertations & Theses, 2018 - 222 p.

Source: Dissertations Abstracts International, Volume: 80-10, Section: B.

Thesis (Ph.D.)--The Johns Hopkins University, 2018.

This item must not be sold to any third party vendors.

Numerous human medical problems or diseases have been aided by the development of effective treatments such as drugs and medical devices. Clinical trials are an integral part of the development process, determining the safety and efficacy of the new proposed treatment, as required by the Food and Drug Administration of the United States. A reliable, efficient and cost-effective way of conducting the clinical trials is important for advancing useful treatments/devices to market and screening out the useless ones, thus benefiting public health in a timely manner. I developed several statistical methods and applications toward this purpose, ranging from early, small scale Phase I studies to late, large scale Phase III studies in clinical trials. In Phase I studies, I establish a general framework for a multi-stage adaptive design where I jointly model a continuous efficacy outcome and continuous toxicity endpoints from multiple treatment cycles, unlike the traditional method that only considers a binary toxicity endpoint (joint work with Mayo Clinic). Extensive simulations confirmed that the design had a high probability of making the correct dose selection and good overdose control. To our best knowledge, this proposed Phase I dual-endpoint dose-finding design is the first to incorporate multiple cycles of toxicities and a continuous efficacy outcome. I also propose and evaluate a two-stage, adaptive clinical trial design for Phase II studies. Its goal is to determine whether future phase 3 (confirmatory) trials should be conducted, and if so, which population should be enrolled. I compute an approximate Bayes optimal design considering a combination of future health benefits and costs. Turning to Phase III studies, I analyze the performance of adaptive enrichment designs with delayed outcome, leveraging information in baseline variables and short-term outcomes to improve precision by using semiparametric, locally efficient estimators at each interim analysis. I also propose a prediction method for analyzing heterogeneity in treatment response, as a secondary analysis, through the identification of treatment covariate interactions honoring different hierarchical conditions.

ISBN: 9781392068441Subjects--Topical Terms:

517247
Statistics.

Statistical Methods in Clinical Trial Design.
LDR:03342nmm a2200337 4500 001 2210842
005 20191121124320.5
008 201008s2018 ||||||||||||||||| ||eng d
020 $a 9781392068441
035 $a (MiAaPQ)AAI13890134
035 $a (MiAaPQ)0098vireo:3684Du
035 $a AAI13890134
040 $a MiAaPQ $c MiAaPQ
100 1 $a Du, Yu. $3 3437986
245 1 0 $a Statistical Methods in Clinical Trial Design.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2018
300 $a 222 p.
500 $a Source: Dissertations Abstracts International, Volume: 80-10, Section: B.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisor: Wu, Albert.
502 $a Thesis (Ph.D.)--The Johns Hopkins University, 2018.
506 $a This item must not be sold to any third party vendors.
506 $a This item must not be added to any third party search indexes.
520 $a Numerous human medical problems or diseases have been aided by the development of effective treatments such as drugs and medical devices. Clinical trials are an integral part of the development process, determining the safety and efficacy of the new proposed treatment, as required by the Food and Drug Administration of the United States. A reliable, efficient and cost-effective way of conducting the clinical trials is important for advancing useful treatments/devices to market and screening out the useless ones, thus benefiting public health in a timely manner. I developed several statistical methods and applications toward this purpose, ranging from early, small scale Phase I studies to late, large scale Phase III studies in clinical trials. In Phase I studies, I establish a general framework for a multi-stage adaptive design where I jointly model a continuous efficacy outcome and continuous toxicity endpoints from multiple treatment cycles, unlike the traditional method that only considers a binary toxicity endpoint (joint work with Mayo Clinic). Extensive simulations confirmed that the design had a high probability of making the correct dose selection and good overdose control. To our best knowledge, this proposed Phase I dual-endpoint dose-finding design is the first to incorporate multiple cycles of toxicities and a continuous efficacy outcome. I also propose and evaluate a two-stage, adaptive clinical trial design for Phase II studies. Its goal is to determine whether future phase 3 (confirmatory) trials should be conducted, and if so, which population should be enrolled. I compute an approximate Bayes optimal design considering a combination of future health benefits and costs. Turning to Phase III studies, I analyze the performance of adaptive enrichment designs with delayed outcome, leveraging information in baseline variables and short-term outcomes to improve precision by using semiparametric, locally efficient estimators at each interim analysis. I also propose a prediction method for analyzing heterogeneity in treatment response, as a secondary analysis, through the identification of treatment covariate interactions honoring different hierarchical conditions.
590 $a School code: 0098.
650 4 $a Statistics. $3 517247
650 4 $a Health sciences. $3 3168359
690 $a 0463
690 $a 0566
710 2 $a The Johns Hopkins University. $b Biostatistics. $3 3437984
773 0 $t Dissertations Abstracts International $g 80-10B.
790 $a 0098
791 $a Ph.D.
792 $a 2018
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13890134